Wellness Intervention for Smoking and HIV

Korábbi kezelés

• Unstable drug use that precludes reliable study participation as assessed by study physician;
• Any prior history of seizure disorder within the past year;
• Currently working night/rotating shift and/or use of a sleep medication, or a medication that could influence sleep;
• Prior history of adult somnambulism;
• Use of a sleep medication that will interfere with study results

Más betegség

• Unstable mental illness that precludes reliable study participation as assessed by study physician;
• A history of a suicide attempt within the last two years, and/or current nonspecific suicidal thoughts as defined by the Columbia Suicide Severity Rating Scale;
• Serious or unstable disease within the past 6 months (e.g., cancer, seizure disorder, end-stage liver disease, end-stage renal disease, uncontrolled diabetes, pulmonary disease requiring oxygen);
• Unstable cardiac condition (i.e., angina, myocardial infarction, or coronary angioplasty) within the past 6 months or a clinically significant EKG that may present a health or safety risk as assessed by the study physician;

Egyéb

• Regular use of chewing tobacco, snuff, cigars, e-cigarettes, unless willing to stop;
• Current enrollment or plans to enroll in another smoking cessation program or use other smoking cessation products for the duration of the study;
• Women of childbearing potential who are pregnant, lactating, or likely to become pregnant during the trial and unwilling to use contraception during the study;
• Unstable alcohol use that precludes reliable study participation as assessed by study physician;
• Unstable or untreated moderate or severe depression as assessed by the Patient Health Questionnaire 9 (PHQ-9) scale. A participant with a score of ≥ 15 will be referred to one of the study's mental health clinicians (Dr. Michael Grandner or Dr. Susan Gorovoy) for further assessment of their depression
• Inability to complete any of the study tasks as determined by the investigators.

• Males and females 18 -75 years;
• Documented HIV infection;
• CD4+ T cell count ≥ 200 cells/mm3;
• On stable antiretroviral therapy without intention of changing, or not on antiretroviral therapy with no immediate intention to start;
• Smoke at least 5 cigarettes/day;
• Report wanting to quit smoking in the next month;
• Have no sleep disorders (with the exception of insomnia or mild to moderate obstructive sleep apnea (STOP-Bang score of 4 or less; apnea-hypopnea index (AHI) of less than 30);
• Able to communicate in English and provide written informed consent for study procedures;
• Able to use varenicline tartrate safely;
• Will be residing in the geographic area for at least 10 months;
• Willing to attend 8 in-person sessions and one 6-month follow up assessment.